

REMARKS

Claims 1-12, 15-55, 58, 61 and 73-76 are now allowed. In the instant Amendment, claim 12 is cancelled, without prejudice. Upon a review of the allowed claims, it was noticed that claim 12 was inadvertently included as part of the claim set, as it does not pertain to a part of the allowed claim 1 from which it depends, i.e., there is no antecedent basis for the subject matter of claim 12.

Claim 37 is amended to reflect consistent verbiage with that used in Claim 22 to define variable R^3 .

Claims 1, 18, 21, 50 and 52 have been amended to correct various punctuation errors. In particular,

Claim 1 is amended to delete unnecessary colons (:) and dashes (-) and if needed, a comma (,) inserted in place thereof;

Claim 18 is amended to insert a comma (,) after the term "thienyl";

Claim 21 is amended to insert a comma (,) after the first occurrence of the term "wherein"; and

Claims 50 and 52 are amended to correct the inadvertent recitation of two compounds without the appropriate separation punctuation, i.e., a semicolon (;), between them. Such inadvertent recitation was clarified by inserting a semicolon (;) after the named compound "4-(3-aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile," and before the named compound "[4-(3-aminomethylphenyl)piperidin-1-yl]-(3,4-dichlorophenyl)methanone".

The above amendments to the claims do not introduce new matter. Applicants respectfully request entry of the amendments such that the corrections are noted with the issuance of the patent. The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982 in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

Dated: June 7, 2005


Julie Anne Knight, Registration No. 48,867
Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3679
Telefax: 908-231-2626
Docket No. USCA2413 US NP